Phase Forward and Merck Team Up to Win Society for Clinical Data Management Data Driven Innovation Award
October 14 2009 - 1:15PM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced that a joint project with customer Merck & Co. has
won the 2009 Society for Clinical Data Management (SCDM) Data
Driven Innovation Award competition. This annual honor recognizes
the year’s best advancement in clinical data management technology
or service.
The award was announced last week at the 2009 SCDM Annual
Conference, the industry’s largest education event for clinical
data management professionals. The Phase Forward/Merck project was
selected from among five industry finalists.
The winning project and new solution, Direct Data Loader, more
efficiently loads external data, such as lab safety and biomarker
data. As a result, external data can be integrated more rapidly and
accurately into Merck’s electronic data capture (EDC) system –
Phase Forward’s InForm™ solution.
With Direct Data Loader, the load rate into the InForm system
was increased from a maximum 1,000 records per hour with the
previous solution, to an estimated 100,000 records per hour. The
new solution also improved the “data currency” within InForm
trials, especially as related to activities that depend on data
reporting, including time-sensitive Serious Adverse Event reporting
efforts. Direct Data Loader has proven to be instrumental in
eliminating the backlog of unloaded data, preventing future backlog
and saving staff time.
“We’re honored to share this award recognizing the creative and
collaborative efforts of the Merck/Phase Forward team,” said Bob
Weiler, chairman and CEO, Phase Forward. “From its inception, when
the team solicited feedback from stakeholders in the process to
define the project, through its development and implementation, the
team focused on its objectives of delivering a high performance
solution while achieving the greatest business benefit
possible.”
“SCDM was thrilled with the quantity and quality of entries in
the third annual Data Driven Innovation Award,” said Brenda Hoeper,
conference co-chair. “We feel privileged to recognize innovations
in the CDM discipline that have demonstrated evidence of adding
value to the clinical trial process.”
About the Society for Clinical Data Management
The Society for Clinical Data Management is a nonprofit
professional organization dedicated to promoting excellence in
clinical data management through professional development,
education and certification. Established in 1994, SCDM has more
than 2,600 members with an interest in advancing data management
practices. For additional information, please visit
www.scdm.org.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 290 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, the performance and features of Phase Forward’s
products and services, demand for Phase Forward’s products and
services, future business and operations plans of a Phase Forward
customer, and the ability of Phase Forward’s customers to realize
benefits from the use of Phase Forward’s products and services.
These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond Phase Forward's control, which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include,
among other things, the ability of Phase Forward’s customers to
realize benefits from the use of its products and services, the
possibility that customers’ needs or plans may change over time,
the possibility that the level of demand for Phase Forward’s
products and services may vary, regulatory changes and competition.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise. For additional disclosure regarding
these and other risks faced by Phase Forward, see the disclosure
contained in Phase Forward's public filings with the Securities and
Exchange Commission including, without limitation, its most recent
Annual Report on Form 10-K.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024